Plain-English translation of NCT06999031 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing CG-105-12, a new type of cancer treatment made from your own immune cells. Researchers take your T cells (a type of white blood cell), reprogram them in the laboratory to recognize and attack myeloma cancer cells, and then infuse them back into your body. The study aims to learn whether this treatment is safe and whether it can help patients whose multiple myeloma no longer responds to standard medicines.
Multiple myeloma patients often develop resistance to current treatments, leaving them with limited options. This medication is designed to work in a new way by teaching the immune system to directly target and destroy myeloma cells, offering hope for patients who have exhausted other therapies.
You likely qualify if…
You likely don't qualify if…
If you enroll, doctors will first collect some of your blood to extract and reprogram your T cells in a laboratory — this process typically takes several weeks. Once your cells are ready, you will receive an infusion of the reprogrammed cells back into your body. Throughout the study, you will have multiple visits for blood tests, imaging scans, and check-ups to monitor how well the treatment is working and whether you experience any side effects. The trial expects to enroll 7 to 12 patients total and is being conducted at a single hospital in China.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
China